CN117279624A - 用于提高工程化二聚体蛋白稳定性的水溶液组合物 - Google Patents

用于提高工程化二聚体蛋白稳定性的水溶液组合物 Download PDF

Info

Publication number
CN117279624A
CN117279624A CN202280028860.9A CN202280028860A CN117279624A CN 117279624 A CN117279624 A CN 117279624A CN 202280028860 A CN202280028860 A CN 202280028860A CN 117279624 A CN117279624 A CN 117279624A
Authority
CN
China
Prior art keywords
leu
val
lys
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280028860.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·阿玛努拉
J·杰泽克
D·杰林
J·克雷明
J·平托
B·洛博
B·海耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CN117279624A publication Critical patent/CN117279624A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280028860.9A 2021-02-17 2022-02-17 用于提高工程化二聚体蛋白稳定性的水溶液组合物 Pending CN117279624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2102258.7A GB202102258D0 (en) 2021-02-17 2021-02-17 Novel composition
GB2102258.7 2021-02-17
PCT/US2022/016864 WO2022178175A1 (en) 2021-02-17 2022-02-17 Aqueous solution compositions for increasing stability of engineered dimeric proteins

Publications (1)

Publication Number Publication Date
CN117279624A true CN117279624A (zh) 2023-12-22

Family

ID=75338972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280028860.9A Pending CN117279624A (zh) 2021-02-17 2022-02-17 用于提高工程化二聚体蛋白稳定性的水溶液组合物

Country Status (12)

Country Link
US (2) US20220265788A1 (cg-RX-API-DMAC10.html)
EP (1) EP4294372A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024506718A (cg-RX-API-DMAC10.html)
KR (1) KR20230147140A (cg-RX-API-DMAC10.html)
CN (1) CN117279624A (cg-RX-API-DMAC10.html)
AU (1) AU2022224607A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023016442A2 (cg-RX-API-DMAC10.html)
CA (1) CA3208704A1 (cg-RX-API-DMAC10.html)
GB (1) GB202102258D0 (cg-RX-API-DMAC10.html)
IL (1) IL305142A (cg-RX-API-DMAC10.html)
MX (1) MX2023009630A (cg-RX-API-DMAC10.html)
WO (1) WO2022178175A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225513A1 (en) * 2022-05-16 2023-11-23 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312136A1 (en) * 2003-11-14 2008-12-18 Manzer Durrani Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions
CN107206257A (zh) * 2014-10-27 2017-09-26 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制剂融合多肽和其使用方法
CN111511351A (zh) * 2017-12-22 2020-08-07 艾瑞克有限公司 新型组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP4965446B2 (ja) * 2004-08-31 2012-07-04 ノヴォ ノルディスク アー/エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス(ヒドロキシメチル)アミノメタンの使用
JP2008543839A (ja) * 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
KR20080071192A (ko) * 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
SMT201900520T1 (it) 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US9527890B2 (en) * 2013-06-18 2016-12-27 The Brigham And Womens's Hospital, Inc. FC receptor (FcRn) binding peptides and uses thereof
CN110903398B (zh) * 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312136A1 (en) * 2003-11-14 2008-12-18 Manzer Durrani Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions
CN107206257A (zh) * 2014-10-27 2017-09-26 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制剂融合多肽和其使用方法
CN111511351A (zh) * 2017-12-22 2020-08-07 艾瑞克有限公司 新型组合物

Also Published As

Publication number Publication date
BR112023016442A2 (pt) 2023-10-10
US20220265788A1 (en) 2022-08-25
AU2022224607A1 (en) 2023-08-31
WO2022178175A1 (en) 2022-08-25
US20250177501A1 (en) 2025-06-05
KR20230147140A (ko) 2023-10-20
CA3208704A1 (en) 2022-08-25
GB202102258D0 (en) 2021-03-31
EP4294372A1 (en) 2023-12-27
MX2023009630A (es) 2023-11-06
IL305142A (en) 2023-10-01
JP2024506718A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
CN104224705B (zh) 稳定化的液体和冻干的adamts13制剂
EP3715371A1 (en) Belimumab formulation
CN104010657A (zh) 氯化钠稳定的依那西普制剂
WO2011141926A2 (en) Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
CN104661651A (zh) 表现出不溶性微粒显著减少的依那西普制剂
JP7357540B2 (ja) 液体医薬組成物
CN101687038A (zh) 新型制剂
CN114917185A (zh) 药物配制品及其制备方法
US20260077016A1 (en) Novel composition comprising antibodies
US20240424059A1 (en) Formulations for VEGF Receptor Fusion Proteins
TWI752912B (zh) 那他珠單抗的穩定水性調配物
KR20230147140A (ko) 조작된 이량체 단백질의 안정성을 증가시키기 위한 수용액 조성물
HK40104639A (en) Aqueous solution compositions for increasing stability of engineered dimeric proteins
JP2025020122A (ja) 安定化Fc融合タンパク質溶液
JP2024506718A5 (cg-RX-API-DMAC10.html)
JP2024507347A (ja) Fcドメインを含む操作されたタンパク質コンストラクトの水性組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40104639

Country of ref document: HK